FOR LABORATORY RESEARCH USE ONLY — not for human or veterinary use, diagnosis, treatment, or cosmetic application. Buyers must be 21+ and legally permitted to purchase research chemicals in their jurisdiction.Intended-use statement →
FOXO4-DRI Wholesale
D-Retro-Inverso FOXO4-p53 interaction inhibitor — targeted senescent cell clearance research, manufacturer-direct
Product Identity
| CAS Number | — (D-Retro-Inverso peptide) |
| Sequence | D-Retro-Inverso 47-mer (all D-amino acids, reversed sequence) |
| Amino Acids | 47 (all D-amino acids, retro-inverso) |
| Molecular Weight | ~4,316.0 Da |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥99% by HPLC |
| Solubility | Soluble in sterile water or PBS |
| Storage | 2–8°C, desiccated, protect from light |
Available Configurations
| Configuration | Content | Best For |
|---|---|---|
| Standard Kit | 5 mg × 10 vials | Senolytic research; evaluation |
| Bulk Kit | 10 mg × 10 vials | Aging models; repeat orders |
| Custom | Custom mg × custom vials | OEM; private-label |
Research Background
FOXO4-DRI (D-Retro-Inverso) is a modified peptide that disrupts the FOXO4-p53 interaction in senescent cells — a mechanism for targeted senescent cell clearance (senolysis). It represents a fundamentally different approach from signaling peptides: rather than modulating a pathway, it targets a specific protein-protein interaction. The D-Retro-Inverso modification (all D-amino acids, reversed sequence) makes the peptide essentially invisible to proteases, conferring dramatically extended half-life. Developed by the de Keizer lab, FOXO4-DRI is a landmark tool in cellular senescence research.
Proposed Mechanisms
Research Focus Areas
p53-mediated senescent cell apoptosis induction
Selective elimination of senescent cells without affecting proliferating cells
Age-related pathology reduction; healthspan extension in rodent models
Doxorubicin-induced senescence and cardiotoxicity mitigation
Quality Specifications
| Parameter | Method | Criterion |
|---|---|---|
| Purity | HPLC at 214 nm, C18 column | ≥99.0% peak area |
| Identity (MW) | MALDI-TOF MS | ~4,316.0 ± 2.0 Da |
| Appearance | Visual inspection | White to off-white powder |
| Chiral Purity | Chiral amino acid analysis | All D-amino acids confirmed |
| Residual Moisture | Karl Fischer | ≤3% |
Tiered Wholesale Pricing
Kit prices are quoted per specification — current list prices for peptide kits run from US$24 to US$339 per kit (10 vials); tiered volume discounts apply (see the tier table) — source:wholesale price list (PDF, updated 2026-08-08).
| Volume | Discount | For |
|---|---|---|
| 1 kit | List price | Evaluation; competitive analysis |
| 5+ kits | 10% off | Initial portfolio expansion |
| 20+ kits | 20% off | Mid-size distributors |
| 50+ kits | 30% off | Regional distributors |
FAQ
What is FOXO4-DRI and how does it work?
FOXO4-DRI is a 47-amino acid D-Retro-Inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells. FOXO4 normally sequesters p53 in the nucleus of senescent cells, preventing apoptosis. DRI displaces FOXO4 → releases p53 → triggers mitochondrial apoptosis cascade → selectively eliminates senescent cells.
What does D-Retro-Inverso mean?
The peptide is synthesized from all D-amino acids (not natural L-form) in reversed sequence order. Result: same 3D side-chain topology as natural L-peptide but completely resistant to proteolytic degradation — proteases only recognize L-amino acids.
How does FOXO4-DRI selectively target senescent cells?
Senescent cells accumulate high FOXO4-p53 complexes as part of their anti-apoptotic survival program. DRI specifically disrupts these. Healthy, proliferating cells have much lower complex levels and are correspondingly less affected.
What is the difference vs other senolytics?
Most senolytics (dasatinib, quercetin) target BCL-2 family proteins broadly. FOXO4-DRI targets a specific protein-protein interaction unique to senescent cell biology — the FOXO4-p53 nuclear complex — potentially providing greater senescent cell selectivity.
What QC is unique to FOXO4-DRI?
Beyond standard tests: chiral amino acid analysis confirms all D-configuration residues; MALDI-TOF MS for accurate mass of this larger 47-amino acid peptide. All in batch-specific COA.
All products are manufactured for laboratory research purposes only. FOXO4-DRI is labeled FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, diagnosis, treatment, prophylaxis or any clinical, cosmetic, dietary or household application. Not a dietary supplement, pharmaceutical ingredient, cosmetic ingredient or approved drug substance. Buyers are responsible for verifying the legal status of importation and possession in their destination country.
Ready to Source FOXO4-DRI?
Bulk pricing, tiered discounts up to 30%, COA with every order.